Suppr超能文献

血管紧张素 II 诱导的交感神经传递促进作用中 AT(2) 受体的参与。

Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.

作者信息

Balt Jippe C, Mathy Marie-Jeanne, Nap Alex, Pfaffendorf Martin, van Zwieten Pieter A

机构信息

Department of Pharmacotherapy, University of Amsterdam, The Netherlands.

出版信息

J Renin Angiotensin Aldosterone Syst. 2002 Sep;3(3):181-7. doi: 10.3317/jraas.2002.039.

Abstract

UNLABELLED

Angiotensin II (Ang II) causes facilitation of sympathetic neurotransmission via prejunctionally-located AT(1)-receptors. The pithed rat is a suitable model to study the interactions between endogenously produced Ang II and the sympathetic nervous system at the peripheral level. Previously, we demonstrated that inhibition of the facilitatory actions of Ang II is a class effect of all AT(1)-receptor blockers (ARB). However, all ARBs caused less than maximal inhibition after the highest dose, thus causing a U-shaped dose-response curve with respect to sympatho-inhibition. In the present study, we investigated whether the AT(2)-receptor is involved in this upturn of the dose-response relationship. Accordingly, we studied the effect of the ARB, irbesartan (1 60 mg/kg), on the sequelae of electric stimulation of the thoraco-lumbar sympathetic outflow in the presence and absence of the AT(2)-blocker, PD 123319 (0.5 mg/kg +50 g/kg/min). Additionally, the effect of the combined (non- selective) AT(1)/AT(2)-receptor antagonist saralasin (0.001, 0.003, 0.01 or 0.03 mg/kg/min), on stimulation-induced responses was studied. In addition, we measured PRA-levels after administration of irbesartan, in this model. The stimulation-induced increase in diastolic blood pressure (DBP) could be dose-dependently reduced by irbesartan. Co-infusion with PD 123319 increased the sympatho-inhibitory potency of irbesartan, possibly through displacement of irbesartan from plasma protein binding sites. The U-shaped dose-response relationship observed with irbesartan, which is illustrative for other ARBs in this model, was not observed when PD 123319 was co-administered with irbesartan, nor with the non-selective AT(1)/AT(2)-blocker, saralasin. PRA-levels increased from 111.0+17.8 to 198.7+22.2 ng/ml/hour after administration of irbesartan. PRA-levels did not differ when measured after the three highest doses of irbesartan.

CONCLUSIONS

The present findings indicate a facilitatory role for the AT(2)-receptor, which is unmasked by the highest dose of irbesartan. Different plasma Ang II-levels are unlikely to have caused the less than maximal inhibition after the highest dose of irbesartan.

摘要

未标记

血管紧张素II(Ang II)通过位于神经节前的AT(1)受体促进交感神经传递。脊髓麻醉大鼠是研究内源性产生的Ang II与外周水平的交感神经系统之间相互作用的合适模型。此前,我们证明抑制Ang II的促进作用是所有AT(1)受体阻滞剂(ARB)的类效应。然而,所有ARB在最高剂量后引起的抑制作用均未达到最大,因此在交感神经抑制方面呈现出U形剂量反应曲线。在本研究中,我们调查了AT(2)受体是否参与了这种剂量反应关系的上升。因此,我们研究了ARB厄贝沙坦(1 - 60 mg/kg)在存在和不存在AT(2)阻滞剂PD 123319(0.5 mg/kg + 50 μg/kg/min)的情况下,对胸腰交感神经传出电刺激后遗症的影响。此外,还研究了联合(非选择性)AT(1)/AT(2)受体拮抗剂沙拉新(0.001、0.003、0.01或0.03 mg/kg/min)对刺激诱导反应的影响。另外,在该模型中,我们测量了给予厄贝沙坦后的肾素活性(PRA)水平。刺激诱导的舒张压(DBP)升高可被厄贝沙坦剂量依赖性降低。与PD 123319共同输注增加了厄贝沙坦的交感神经抑制效力,可能是通过将厄贝沙坦从血浆蛋白结合位点置换出来实现的。当PD 123319与厄贝沙坦共同给药时,未观察到厄贝沙坦呈现的U形剂量反应关系,在使用非选择性AT(1)/AT(2)阻滞剂沙拉新时也未观察到。给予厄贝沙坦后,PRA水平从111.0 + 17.8升高至198.7 + 22.2 ng/ml/小时。在厄贝沙坦的三个最高剂量后测量时,PRA水平没有差异。

结论

目前的研究结果表明AT(2)受体具有促进作用,这在厄贝沙坦最高剂量时被揭示出来。不同的血浆Ang II水平不太可能导致厄贝沙坦最高剂量后抑制作用未达到最大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验